Accéder au contenu
Merck

Principaux documents

Voir toute la documentation

O0391

Olopatadine hydrochloride

≥98% (HPLC)

Synonyme(s) :

(11Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride, AL-4943A, KW-4679, Opatanol, Patanol

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C21H23NO3·HCl
Numéro CAS:
140462-76-6
Poids moléculaire :
373.87
NACRES:
NA.77
PubChem Substance ID:
329818840
UNSPSC Code:
12352200
MDL number:
MFCD00875716
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Quality Level

100

assay

≥98% (HPLC)

form

solid

solubility

H2O: ≥20 mg/mL

storage temp.

room temp

SMILES string

Cl.CN(C)CC\C=C1\c2ccccc2COc3ccc(CC(O)=O)cc13

InChI

1S/C21H23NO3.ClH/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24;/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24);1H/b18-8-;

InChI key

HVRLZEKDTUEKQH-NOILCQHBSA-N

Gene Information

human ... HRH1(3269)

Biochem/physiol Actions

Olopatadine is a dual acting histamine H1-receptor antagonist and mast cell stabilizer.
Olopatadine is a histamine H1 receptor antagonist and mast cell stabilizer. The low level of occupancy H1 receptors in the brain explains the low sedation effect of olopatidine. It is believed that olopatidine is a substrate for P-glycoprotein, which limits its brain penetration.

Still not finding the right product?

Explore all of our products under

pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

signalword

Danger

hcodes

H301,H400

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Acute 1

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000192107
0000192106
0000192107
0000192106
0000133985

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Masahiko Shimura et al.
American journal of ophthalmology, 151(4), 697-702 (2011-01-25)
To evaluate the effectiveness of pre-seasonal treatment with topical olopatadine on the reduction of clinical symptoms of seasonal allergic conjunctivitis (SAC). Prospective interventional case series. Eleven patients with SAC received topical olopatadine in one eye at least two weeks before
Hiroyuki Kamei et al.
Archives of dermatological research, 304(4), 263-272 (2011-12-02)
Since most first-generation antihistamines have undesirable sedative effects on the central nervous systems (CNS), newer (second-generation) antihistamines have been developed to improve patients' quality of life. However, there are few reports that directly compare the antihistaminic efficacy and impairment of
Santa J Ono et al.
Drug design, development and therapy, 5, 77-84 (2011-02-23)
Antihistamines constitute the first line of therapy for allergic conjunctivitis, and are safe and effective in relieving the signs and symptoms of ocular allergy. Despite this, they are less effective than some other drugs in relieving delayed symptoms of allergic
Afficher tous les articles scientifiques apparentés